Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aerie Pharmaceuticals (AERI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,456,519
  • Shares Outstanding, K 45,918
  • Annual Sales, $ 24,180 K
  • Annual Income, $ -232,570 K
  • 60-Month Beta 0.86
  • Price/Sales 62.91
  • Price/Cash Flow N/A
  • Price/Book 7.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.80
  • Number of Estimates 4
  • High Estimate -0.75
  • Low Estimate -0.86
  • Prior Year -1.40
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.01 +7.35%
on 06/14/19
41.44 -19.67%
on 05/21/19
-5.77 (-14.77%)
since 05/17/19
3-Month
31.01 +7.35%
on 06/14/19
50.10 -33.55%
on 03/21/19
-13.69 (-29.14%)
since 03/15/19
52-Week
31.01 +7.35%
on 06/14/19
74.75 -55.46%
on 07/20/18
-30.86 (-48.11%)
since 06/15/18

Most Recent Stories

More News
Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of...

AERI : 33.29 (+4.95%)
Aerie Pharmaceut Falls 3.49% on Heavy Volume: Watch For Potential Rebound

Aerie Pharmaceut (NASDAQ:AERI) traded in a range yesterday that spanned from a low of $32.59 to a high of $34.03. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of...

AERI : 33.29 (+4.95%)
Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of...

AERI : 33.29 (+4.95%)
SmarTrend Watching for Potential Rebound in Shares of Aerie Pharmaceut After 6.31% Loss

Aerie Pharmaceut (NASDAQ:AERI) traded in a range yesterday that spanned from a low of $34.57 to a high of $34.82. Yesterday, the shares fell 6.3%, which took the trading range below the 3-day low of...

AERI : 33.29 (+4.95%)
Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report?

Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AERI : 33.29 (+4.95%)
Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint

Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.

ESALY : 57.8220 (-0.08%)
AERI : 33.29 (+4.95%)
PFE : 42.88 (+0.28%)
OCUL : 4.21 (-3.66%)
Shares of Intra-Cellular T Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (ITCI , RVNC , AERI , NKTR , DERM )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

ITCI : 14.15 (+13.11%)
AERI : 33.29 (+4.95%)
RVNC : 11.32 (+4.24%)
Relatively Good Performance Detected in Shares of Aerie Pharmaceut in the Pharmaceuticals Industry (AERI , DERM , MNK , HZNP , XENT )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

DERM : 9.91 (+5.09%)
AERI : 33.29 (+4.95%)
MNK : 9.01 (-2.91%)
Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates

Aerie (AERI) reports narrower-than-expected Q1 loss. However, Rhopressa lags expectations.

AERI : 33.29 (+4.95%)
BHC : 22.00 (+2.47%)
PFE : 42.88 (+0.28%)
BMY : 48.21 (+1.37%)
SmarTrend Watching for Potential Pullback in Shares of Aerie Pharmaceut After 6.25% Gain

Aerie Pharmaceut (NASDAQ:AERI) traded in a range yesterday that spanned from a low of $39.78 to a high of $40.99. Yesterday, the shares gained 6.2%, which took the trading range above the 3-day high...

AERI : 33.29 (+4.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AERI with:

Business Summary

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's lead `Dual- Action` product and `Triple-Action` products are...

See More

Key Turning Points

2nd Resistance Point 34.80
1st Resistance Point 34.05
Last Price 33.29
1st Support Level 32.14
2nd Support Level 30.98

See More

52-Week High 74.75
Fibonacci 61.8% 58.04
Fibonacci 50% 52.88
Fibonacci 38.2% 47.72
Last Price 33.29
52-Week Low 31.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar